5th May 2022 11:18
PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Approves share buyback of up to USD50 million. Programme follows "follows consultation with shareholders and is consistent with PureTech's capital allocation strategy and stated approach to drive additional value for its shareholders," company says. PureTech says it had USD413.2 million of net cash and cash equivalents at March 31. Given size of balance sheet, PureTech is confident it can return capital to shareholders and also maintain "sufficient cash on hand to deliver" on strategic priorities.
Current stock price: 186.14 pence, up 11%
12-month change: down 53%
By Eric Cunha; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech